Cargando…

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs

BACKGROUND: Drug manufacturers claim that the purpose of financial payments to physicians is to facilitate education about new drugs. This claim suggests 2 testable hypotheses: payments should not be associated with drug revenue and payments for each drug should decline over time as physicians becom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitchell, Aaron P, Mishra Meza, Akriti, Trivedi, Niti U, Bach, Peter B, Gönen, Mithat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Health Outcomes and Economics of Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526499/ https://www.ncbi.nlm.nih.gov/pubmed/35946837 http://dx.doi.org/10.1093/oncolo/oyac160

Ejemplares similares

Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study
por: Mitchell, Aaron P, et al.
Publicado: (2023)

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
por: Flick, E Dawn, et al.
Publicado: (2023)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer
por: Bhatt, Sunil, et al.
Publicado: (2022)

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
por: Shickh, Salma, et al.
Publicado: (2022)

Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
Publicado: (2023)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

Costs of Cancer Care Across the Disease Continuum
por: Kaye, Deborah R., et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
por: Ludwig, Heinz, et al.
Publicado: (2020)

Women Who Are Young, Non‐White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed‐Effects Regression Analysis
por: Politi, Mary C., et al.
Publicado: (2020)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis
por: Nielson, Carrie M., et al.
Publicado: (2021)

COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
por: Borno, Hala T, et al.
Publicado: (2022)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19
por: Klein, Isaac A., et al.
Publicado: (2021)

The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act
por: Roth, Michael, et al.
Publicado: (2022)

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
por: Tan, Ruoding, et al.
Publicado: (2022)

Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective
por: Azoulay, Laurent
Publicado: (2022)

Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum
por: Lai-Kwon, Julia, et al.
Publicado: (2022)

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
por: Raphael, Jacques, et al.
Publicado: (2022)

Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda
por: Kizub, Darya A, et al.
Publicado: (2022)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
por: Perera, Nirosha D, et al.
Publicado: (2023)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study
por: Norris, Susan L, et al.
Publicado: (2012)

Physician Documentation of Sepsis Syndrome Is Associated with More Aggressive Treatment
por: Stoneking, Lisa R., et al.
Publicado: (2015)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

Impact of the prospective payment system on physician charges under Medicare
por: Fisher, Charles R.
Publicado: (1987)

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Rethinking Medicare Payment Adjustments for Quality
por: Averill, Richard F., et al.
Publicado: (2016)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Are payment methods for prescription drugs associated with polypharmacy in older adults in Ireland? Evidence from the TILDA cohort study
por: Varley, Aine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k86h2k7cdm74ollld7ek4qn1q1